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Elastin microﬁbrillar interface proteins (EMILINs) and Multimerins (EMILIN1, EMILIN2,
Multimerin1, and Multimerin2) constitute a four member family that in addition to the
shared C-terminus gC1q domain typical of the gC1q/TNF superfamily members contain a
N-terminus unique cysteine-rich EMI domain. These glycoproteins are homotrimeric and
assemble into high molecular weight multimers. They are predominantly expressed in
the extracellular matrix and contribute to several cellular functions in part associated with
the gC1q domain and in part not yet assigned nor linked to other speciﬁc regions of the
sequence. Among the latter is the control of arterial blood pressure, the inhibition of Bacil-
lus anthracis cell cytotoxicity, the promotion of cell death, the proangiogenic function, and
a role in platelet hemostasis. The focus of this review is to highlight the multiplicity of
functions and domains of the EMILIN/Multimerin family with a particular emphasis on the
regulatory role played by the ligand–receptor interactions of the gC1q domain. EMILIN1
is the most extensively studied member both from the structural and functional point of
view. The structure of the gC1q of EMILIN1 solved by NMR highlights unique characteris-
tics compared to other gC1q domains: it shows a marked decrease of the contact surface
of the trimeric assembly and while conserving the jelly-roll topology with two β-sheets
of antiparallel strands it presents a nine-stranded β-sandwich fold instead of the usual 10-
stranded fold. This is likely due to the insertion of nine residues that disrupt the ordered
strand organization and forma a highly dynamic protruding loop. In this loop the residue
E933 is the site of interaction between gC1q and the α4β1 and α9β1 integrins, and contrary
to integrin occupancy that usually upregulates cell growth, when gC1q is ligated by the
integrin the cells reduce their proliferative activity.
Keywords: α4β1 integrin, gC1q-dependent cell adhesion, cell migration, gC1q NMR solution structure, EMI domain,
extracellular matrix, skin homeostasis
INTRODUCTION
The elastin microﬁbrillar interface protein (EMILIN) and Mul-
timerin family of glycoproteins is part of the large superfam-
ily of collagenous and non-collagenous proteins containing the
gC1q signature (Shapiro and Scherer, 1998; Doliana et al., 1999;
Kishore et al., 2004). A phylogenetic analysis of gC1q sequences
of the 32 proteins present in the human genome carrying this
domain (Tom Tang et al., 2005; Ghai et al., 2007), show that
EMILINs/Multimerins form a small family well distinct from
the rest of the superfamily. Comparison of the coding sequences
of EMILIN/Multimerin family components against Drosophila
melanogaster and other invertebrate genome database gives no
matches, indicating that this gene family emerged during verte-
brate evolution, ﬁrst appearing in lower cordate, where orthologs
of EMILIN1, EMILIN2, and MMRN2 have been identiﬁed (Mei
and Gui, 2008; Milanetto et al., 2008). MMRN1 is present start-
ing from birds, indicating that this member of the family orig-
inated much later during vertebrate evolution. The members of
the EMILIN/Multimerin family exert a diverse range of functions
directly linked to their gC1q domains although several important
functions depend on interactions of soluble proteins and/or cellu-
lar receptors with other domains. Structure, function, and physi-
ological and pathological consequences of the activity and/or lack
of activity of family members will be summarized.
FUNDAMENTAL NOTIONS ABOUT ECM AND INTEGRIN
RECEPTORS
The cells of the microenvironment are embedded in a supporting
network of extracellular matrix (ECM) constituents that include
collagens, elastin, proteoglycans, and glycoproteins (Li et al., 2007;
Zhang and Huang, 2011). The ECM does not constitute a mere
structural scaffold but it elicits profound inﬂuences on cell behav-
ior and affects cell growth, differentiation, motility, and viability
(Bissell et al., 2005;Marastoni et al., 2008;Hynes, 2009; Cukierman
and Bassi, 2010). The complexity of the microenvironment is fur-
ther magniﬁed by the property of ECM molecules to function as
reservoirs of growth factors, cytokines, matrix metalloproteinases
(MMPs), and processing enzymes (Sternlicht and Werb, 2001).
The relative availability of these elements may be affected when
the ECM rearranges during wound healing or tumor progression.
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The cells sense their microenvironment through interactions
with speciﬁc receptors, the integrins. Integrins, a large family of αβ
heterodimeric cell membrane receptors, are key sensory molecules
that translate chemical and physical cues from the dynamic con-
stituents of ECMintobiochemical signals that regulatemany inter-
related cellular processes (Legate et al., 2009). Integrins function
asmechanotransducers transformingmechanical forces created by
the ECMor the cytoskeleton into cellmovement (Chen et al., 2004;
Hynes, 2009; Schwartz, 2010). Eighteenα and eight β subunits have
been so far discovered in mammals and at least 24 different combi-
nations of α/β subunits have been characterized. Integrins display
overlapping ligand speciﬁcity andmany cells expressmultiple inte-
grin receptors for the same ligand. Ligation of different integrin
receptors by a certain ligand may induce different cellular effects
in response to ECM ligation. Following integrin ligation a vari-
ety of downstream signaling events ensue: for instance, integrins
activate survival pathways via the PI3K and MAPK pathways and
act as essential cofactors for growth factors stimulation. Elevated
integrin expression in the absence of appropriate ligands, or in
the presence of natural or synthetic antagonists, promotes apop-
tosis under otherwise permissive growth conditions. Moreover,
integrins coordinate survival or death responses or cell behavior
as a function not only of ECM composition but also of its rela-
tive stiffness (Levental et al., 2009; Provenzano and Keely, 2011).
This dual function provides an elegant mechanism through which
tissue-remodeling events may regulate cell death or survival in
a temporal, ECM-governed manner (Dupont et al., 2011). Thus,
growth factor shortage and deﬁciency of pro-survival stimuli or
absence of integrin activation leads to intracellular signals, mainly
Akt down-regulation, which in turn activate a peculiar type of
apoptosis in substrate-adherent cells, anoikis (Gilmore, 2005).
Similar balances are at work if one considers the other cellular
processes regulated by the many integrin–ECM relationships.
THE EMILIN/MULTIMERIN FAMILY OF PROTEINS
Proteins containing the EMI domain, a cysteine-rich sequence of
approximately 80 amino acids, deﬁne the EMI domain endowed
(EDEN) superfamily in mammals (Braghetta et al., 2004). This
superfamily comprises seven genes, which can be subdivided into
three families on the basis of the major protein domains. The
ﬁrst family is formed by Emu1 and Emu2 genes (Leimeister et al.,
2002) that except for the presence of an EMI domain do not share
structural similarities with the other EDEN members. The second
family comprises only one gene EMILIN-truncated (EMILIN-T)
with a structure similar to the third larger family, but lacking
the C-terminal globular domain of C1q (gC1q). The third is the
EMILIN/Multimerin family. It is characterized by the N-terminal
EMI domain, a central part of the molecule formed by a long
(approximately 700 amino acids) region with high probability
for coiled-coil structures, and a region homologous to the gC1q
domain (Figure 1). The family includes EMILIN1 (Colombatti
et al., 1985; Bressan et al., 1993; Doliana et al., 1999), EMILIN2
(Doliana et al., 2001), Multimerin1 (MMRN1; Hayward et al.,
1991, 1995), and Multimerin2 (MMRN2; Sanz-Moncasi et al.,
1994; Christian et al., 2001). Apart from MMRN1 that is deposited
in the ECMbut for themost part is sequestered inmegakaryocytes,
endothelial cells (ECs), and platelets granules (Adam et al., 2005),
the members of the EMILIN family are constituents of the ECM
Under normal conditions the expression of each individual gene
overlaps with those of some other members of the family; the only
exception is apparently the central nervous system, where only
EMILIN2 is detected outside blood vessels, at least at the mRNA
level (Braghetta et al., 2004). Moreover, EMILIN2 is speciﬁcally
and abundantly expressed in mouse cochlear basilar membrane
(Amma et al., 2003).
DOMAIN ORGANIZATION
The EMI domain (Doliana et al., 2000a) is located at the N-
terminus in all the proteins in which it is expressed and displays a
high sequencehomology ranging from60 to70%between the fam-
ily members. Cysteine-rich repeat modules are present in various
ECM proteins, including several constituents or proteins associ-
ated with the elastic ﬁber (Pereira et al., 1993; Sinha et al., 1998;
Doliana et al., 2000a). The EMI domain is rather unique: in fact,
while most of the cysteine-rich domains described to date contain
either six or eight cysteine residues, it has seven cysteine residues
located at regular positions, with the exception of MMRN1 in
which the second cysteine residue is missing. The speciﬁc spac-
ing of cysteines and a number of strongly conserved aromatic
and hydrophobic residues represent a diagnostic feature of this
sequence. The consensus WRCCPG(Y/F)xGxxC toward the C-
terminus of the domain is highly preserved and apparently unique
of the EMI domain. Together with the invariable N-terminal posi-
tion in all proteins discovered to date it clearly distinguishes the
EMI domain from other cysteine-rich domain as, for example, the
EGF-like that are often embedded within the protein sequence.
In the last decade on the basis of reiterated sequence homology
searches other proteins including Drosophila CED-1, fasciclin, and
periostin have beenproposed to harbor anEMIdomain (Callebaut
et al., 2003). However, after careful comparison reﬁned by eye, it
appears that these cysteine-rich domains very scarcely conform to
the EMI domain consensus motif and should be classiﬁed as novel
entities.
A few ECM proteins present long domains in which the 3–4–3–
4 spacing of hydrophobic residues (heptad repeats) predicts that
they form α-helical coiled-coils which result in a rigid rod (Berger
et al., 1995; Wolf et al., 1997). The large central regions of all the
EMILIN/Multimerin family members shows a very low or unde-
tectable homology at the primary sequence level; however, when
analyzed by speciﬁc algorithms it reveals a common structural
homology as all the members contain several regions in which the
probability for coiled-coil formation is very high.
Between the long central coiled-coil part of the molecules
and the gC1q C-terminal domain each component of the family
presents different sequences that could confer speciﬁc structural
and/or functional properties. EMILIN1 presents a 90 residues long
sequence, including two sequences corresponding to structures
referred to as “leucine zipper.” Although its precise function has
not been determined yet it might contribute to the coiled-coil
association in the C- to N-terminal direction for the assembly
of a proper EMILIN1 trimer (see below). Right downstream the
leucine zipper there is a short collagenic region formed by 17
GXY triplets organized in a trypsin-resistant triple helix (Mon-
giat et al., 2000). In place of the leucine zipper motif EMILIN2
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FIGURE 1 | Graphical view of EMILIN/Multimerin family members. Note
that: (i) EMI domain: there is some experimental evidence suggesting that
EMI domains might self-interact; however, since it is not clear if they form
trimers they are depicted separated; (ii) Coiled-coil regions: the similarity
between the central regions of the family members is only structural, the
heptad repeats are placed in different positions along the primary sequence
of the different members of the family. (iii) the so called “UNIQUE REGION”
is represented in EMILIN1 by two leucine zippers followed by a functional
17 triplets long collagenic sequence; in EMILIN2 by a proline rich sequence
followed by a non-functional 17 triplets long collagenic sequence; in
MMRN1 by an arginine rich sequence; in MMRN2 by an EGF-like domain;
(iv); the gC1q of EMILIN1 and EMILIN2 possess three unstructured loops
(black triangles) each bearing a glutamic acid (E) able to interact with the
α4β1 integrin.
harbors a unique proline-rich motif of 53 residues that is highly
hydrophilic and exposed to the solvent and thus available for
potential interactions with other ligands or provide some ﬂexi-
bility that is not present in EMILIN1. Just upstream of the gC1q
domain EMILIN2 also presents a collagenous sequence consisting
of 17 triplets like EMILIN1, but with four interruptions, which
makes it very unlikely that this sequence could form a stable
triple helix. MMRN1 and MMRN2 do not harbor any collage-
nous sequence. On the contrary, in the corresponding position
MMRN1 presents an EGF-like domain and MMRN2 an arginine
rich sequence, whose functions are still undisclosed.
The gC1q domain lengths vary between 131 (C1q-C chain of
C1q) and 151 (EMILIN1) residues with a high level of conserva-
tion of several hydrophobic and uncharged residues. Long before
the ﬁrst crystal structure was resolved Fourier-transform infrared
spectroscopy and structure prediction of 15 gC1q sequences sug-
gested a β-sheet secondary structure arrangement for this domain
(Smith et al., 1994). The structurewas then formally demonstrated
by the analysis of the ACRP30/AdipoQ C1q crystal (Shapiro and
Scherer, 1998) followed by the solution of the crystal structures
of the gC1q of human collagen X (Bogin et al., 2002), mouse
collagen VIII (Kvansakul et al., 2003), and human complement
gC1q (Gaboriaud et al., 2003). All these crystals show similar qua-
ternary structures obtained by the non-covalent association of
three polypeptides whose tertiary structure adopts invariability a
beta sandwich topology formed by 10 beta strands organized in
two beta sheets. We were then the ﬁrst to determine the three
dimensional NMR solution structure of the human EMILIN1
gC1q homotrimer (Verdone et al., 2004, 2008, 2009). This domain
exhibits a striking homology to the gC1q domains of several
other members of the C1q/TNF superfamily but, at the same
time, displays very peculiar characteristics (Figure 2). The quater-
nary structure of the complex is formed by three mostly identical
subunits, apart from very minor differences inherently associated
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FIGURE 2 |Top: NMR solution structure of the homotrimeric EMILIN1
gC1q domain.The structure was downloaded from database of protein
structures maintained at NCBI site (http://www.ncbi.nlm.nih.gov/Structure/
mmdb/mmdbsrv.cgi?uid=68072). Ribbon representation of the assembly,
as side view, is presented in (A) the three protomers in the trimer are
shown in different colors (pink, blue, and brown). Each monomer has a
nine-stranded folding topology, with strands labeled according to the
gC1q/tumor necrosis factor superfamily nomenclature. (B)The residues
highly conserved in all the members of the gC1q superfamily and essential
for a correct domain folding are shown in yellow only in one monomer for
clarity. (C)Top view of EMILIN1 gC1q domain. The yellow bar highlights the
solvent exposed position of the unstructured segment Tyr927–Gly945
(D) the X-ray structure of type VIII collagen gC1q, http://www.ncbi.nlm.nih.
gov/Structure/mmdb/mmdbsrv.cgi?uid=25284, showing the buried
position of strand F. The same position of strand F is present in the X-ray
solution structures of ACRP, type X collagen and Complement gC1q
domains. Bottom: Sequence alignment between strand F (residues in bold)
of representative members of the C1q superfamily and EMILINs gC1q.
Asterisks indicate proteins for which the structure has been solved. Similar
residues that are conserved in all proteins are shaded in gray, and the
glutamic acid residue interacting whit α4β1 is in yellow.
with the molecular dynamic simulations (Verdone et al., 2008,
2009). Each protomer conserves the typical jelly-roll topology of
two β-sheets of antiparallel strands. However, in contrast to all
the gC1q structures solved to date, it presents a nine-stranded
β-sandwich fold instead of the 10-stranded fold. By sequence
homology alignment of C1q family members, the lack of the F
beta strand in EMILIN1 gC1q may be due to the insertion of
nine residues in the middle of strand F that disrupt its secondary
structure. As an important consequence, the highly ordered and
rigid strand is substituted by a 19-residues long segment spanning
from Y927 to G945. This sequence is unfolded, highly dynamic
and highly accessible to solvent, with 10–11 residues protrud-
ing from the main globular structure making this region a good
candidate for hosting an interaction site. Indeed, by site-directed
mutagenesis experiments focused on this segment, we mapped
the acidic residue E933 as the site of interaction between gC1q
and the α4β1 integrin. This loop is not present in any of the
already determined gC1q structures, and seems the only region
of gC1q where single mutation or even deletions do not alter the
overall domain structure. Interestingly, the quaternary structure
of EMILIN1 gC1q assembly locates the unstructured loop at the
apex of the homotrimer (Figure 2D). Another important infor-
mation derived from the NMR solution structure of the EMILIN1
gC1q is a marked decrease of the monomer contact surface in
the trimeric assembly (3,000 Å2), compared to ACRP (5,324 Å2),
complement (5,490 Å2), Type VIII (6,150 Å2), and type X colla-
gen (7,360 Å2) gC1q domains. Since the conserved residues are
nearly identical in the different gC1q domains, it seems reasonable
that the lower thermal stability detected in some of the domains,
namely ACRP30 and EMILIN1 depends on the partly different
neighboring residues among the various domains. Moreover, the
decrease of the buried surface may in part be due to the missing
contribution of unstructured element, or even to a contact dis-
turbing activity, as suggested by the decrease of trimer thermal
stability observed in some mutants (Doliana et al., unpublished
data). Despite various attempts, we were unable to express a sol-
uble form of EMILIN2 gC1q domain and hence to determine its
structure, but, based on the sequence homology and functional
data, it is conceivable that also the gC1q of EMILIN2 presents the
same unstructured loop able to interact with the integrin receptor
(see below). None of the other gC1q of the superfamily possess the
described unstructured insertion and there are no data on a pos-
sible interaction with the α4β1 integrin. It is of note that the E993
residue is the only site of interaction with an integrin localized to
date in a gC1q domain.
GENOMIC ORGANIZATION
The EMI domain of EMILIN1 is contained in exons 2 and 3
(Doliana et al., 2000b) and the organization of this domain is
remarkably similar to that of EMILIN2 (Doliana et al., 2001). Exon
4 (almost 2000 bp in length) encodes for four coiled-coil structures
and two leucine zippers which may represent a sort of functional
unit. The short collagenous region of EMILIN1 is encoded by two
very short exons (5, 6) and part of exon 7. Finally, the gC1q domain
is encoded by part of exon 7 and exon 8. Similarly to EMILIN1 also
the EMILIN2 gene consists of eight exons and seven introns. How-
ever, whereas the exon structure is remarkably similar between the
two genes, several introns of EMILIN2 are much larger than those
of EMILIN1 resulting in an overall gene size of about 40 kb as
opposed to the remarkably compact EMILIN1 gene (8 kb). Never-
theless, the exon size pattern and location of introns in the coding
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sequence are verywell conserved between the two genes likely indi-
cating that they evolved from a common ancestor. Whereas most
of gC1q domains are encoded within one exon, with the notable
exception of cerebellin family where the coding sequence is split-
ted in three exons, those of EMILIN1 and EMILIN2 are encoded
by two exons. MMRN1 and MMRN2 genes have a similar organi-
zation with EMILINs genes only limited to the EMI domain and
the large exon coding for the coiled-coil structures. At variance,
MMRNs present two additional short exons interposed between
the EMI domain coding exons and the coiled-coil coding exon. In
both genes the gC1q domain is encoded within a single exon.
Before describing in more detail the functions of
EMILIN1/Multimerin family formally associated with the gC1q
domain, a short summary of the various functions of
EMILIN/Multimerin proteins not directly dependent gC1q will
follow (Figure 3).
gC1q-INDEPENDENT FUNCTIONS
EMILIN1 AND BLOOD PRESSURE CONTROL
Arterial blood pressure is a function of the vasculature resistance
and of the cardiac output, i.e., the amount of blood pumped out
by the heart. The integrity and elasticity of the vessels and the
modulation of blood pressure are determined by smooth muscle
cells and ECs lining the vascular walls and by their relationship
with ECM. EMILIN1 is intimately associated with elastic ﬁbers
and microﬁbrils in blood vessels (Colombatti et al., 1985, 2000).
EMILIN1 is implicated in elastogenesis and in maintenance of
blood vascular cell morphology (Zanetti et al., 2004). Emilin1−/−
mice display elevated systemic blood pressure independent of car-
diac output without defects in vascular contractility or mechanical
properties. They have signiﬁcantly narrower arteries causing the
hypertensive phenotype. EMILIN1 binds to proTGF-β1 prior to
the cleavage of LAP and upstream of the furin convertases and
prevents its processing (Zacchigna et al., 2006). The increased
TGF-β in the absence of EMILIN1 as it occurs in Emilin1−/− mice
leads to reduced vascular cell proliferation and results in narrower
blood vessels and increased peripheral resistance, thereby causing
hypertension. Also Emilin2−/− and MMRN2−/− mice mice dis-
play hypertensive phenotypes but the underlying mechanisms are
different and do not affect proTGF-β1 processing (G. M. Bressan
et al., unpublished data). While the pathogenetic mechanism of
blood hypertension is largely explained by the interaction between
the EMI domain and proTGF-β, EMILIN1 may also be involved in
the hypertensive phenotype with other domains; for instance, in
anchoring smooth muscle cells to elastic ﬁbers or in the process of
vessel assembly. In fact, in the media of arteries there are speciﬁc
sites of interaction between smooth muscle cells and elastic ﬁbers
(Daga-Gordini et al., 1987). At these sites the cell basement mem-
branes are interrupted and the cell surface is in direct contact with
the periphery of the amorphous elastin core, a region enriched in
ﬁbrillin (Sakai et al., 1986) andEMILIN1 (Bressan et al., 1993). The
ﬁnding that EMILIN1 gC1q is an adhesive substrate (see below)
and provides anchorage and/or homeostatic control of cell prolif-
eration (see below) suggests that it might also contribute to affect
the cell number and the size of smooth muscle cells in arterial
walls.
FIGURE 3 |The functions ascribed to the gC1q domain and to the
other domains of EMILIN1 and EMILIN2 are summarized to show
the versatility of these glycoproteins.The regulation of elastogenesis
and of lymphangiogenesis have not yet been pinpointed to a speciﬁc
domain although it is tempting to assume that gC1q plays an important
role.
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DEFENSE FUNCTION OF EMILIN/MULTIMERIN FAMILY MEMBERS
The informational spectrummethod (ISM), a virtual spectroscopy
approach, is a fast and simple structure analysis of proteins and
their functionally important domains (Veljkovic and Metlas, 1988;
Shepherd et al., 2003; Wen et al., 2005). By applying the ISM
to the human sequence database all EMILIN/Multimerin family
members were predicted to interact with anthrax protective anti-
gen (PA). The interaction with PA was then formally proven for
EMILIN1 and EMILIN2 by solid phase assays using recombinant
proteins (Doliana et al., 2008). The interacting part of EMILIN2
resides in the ﬁrst N-terminal 108 residues. Residue D425 of PA is
important inmediatingBacillus anthracis cell toxicity (Ahuia et al.,
2003) and its deletion results in a PA variant which still assembles
but forms non-functional complexes leading to a complete inhi-
bition of the channel forming ability of PA (Sellman et al., 2001).
The deletion mutant (del425) of PA binds to EMILIN1 with very
low efﬁciency suggesting that EMILIN1 interacts with this residue
to prevent cell toxicity. The interaction is independent of the pres-
ence of divalent cations and does not involve PA aspartic residue
at 683, a critical residue in cell surface receptor binding. The func-
tional consequences of the speciﬁc interaction of PA in vitro and
the inhibition of cell cytotoxicity by the LF–PA complex in the
presence of EMILIN1 suggests that EMILINs/Multimerins, along
with the LDL receptor-related protein LRP6 (Mayer et al., 2001),
represent additional targets and/or binding proteins potentially
useful for countermeasures against B. anthracis toxin lethality.
EMILIN2 AND CELL DEATH PROMOTION
Among the few ECM molecules that impair cell viability (Shichiri
and Hirata, 2001; Todorovicç et al., 2005; Seidler et al., 2006;
Ramakrishnan et al., 2007; Tai and Tang, 2008; Juric et al., 2009)
EMILIN2 adopts an entirely different mechanism, i.e., the activa-
tion of the extrinsic apoptotic pathway through a direct binding to
death receptor 4 (DR4) and 5 (DR5; Pan et al., 1997; LeBlanc and
Ashkenazi, 2003). This binding, in analogy with the downstream
events that occur after ligation of the death ligand TRAIL to DR4
or DR5, is followed by receptor clustering, co-localization with
lipid rafts, DISC assembly, and caspase activation (Mongiat et al.,
2007). Thus, EMILIN2 mimics the activity of the known death
receptor ligands (Walczak et al., 1997; Ashkenazi, 2008; Johnstone
et al.,2008). This pro-apoptotic function resides in ahomotrimeric
90 residues long region toward the N-terminus of the molecule,
positioned right after the EMI domain in the coiled-coil domain
(Mongiat et al., 2010). Since normal cells do not express DR4
or DR5 it can be speculated that EMILIN2 or speciﬁc peptides
encompassing the pro-apoptotic region might be used as anti-
tumor agents in combination with anti-angiogenic drugs such as
bevacizumab (Mongiat et al., 2010) and in cases where TRAIL
resistance is involved (Hengartner, 2000; Fulda, 2009).
MMRN2, EMILIN2, AND ANGIOGENESIS
MMRN2 is found along the blood vessels in close contact with
ECs in normal and tumor vasculature (Sanz-Moncasi et al., 1994;
Christian et al., 2001; Koperek et al., 2007) and contributes to
the maintenance of blood vessels’ homeostasis by affecting the
VEGF-A/VEGFR2 axis (Lorenzon et al., 2011). Neither prolifera-
tion nor apoptotic rate are affected. By preventing the interaction
of VEGF-A with VEGFR1 and VEGFR2, MMRN2 reduces their
activation and impaires the non-integrin dependent motility of
ECs leading to a decreased intra-tumoral angiogenesis and con-
sequent impaired tumor growth. It is conceivable that MMRN2
attains a high EC pericellular concentration and thus competes
for the binding of VEGF-A to its receptors. MMRN2 may thus
represent a novel key homeostatic molecule indispensable for the
maintenance of blood vessel integrity.
Despite the strong reduction of tumor growth induced by the
pro-apoptotic function of EMILIN2 (Mongiat et al., 2007, 2010),
EMILIN2 also increases the overall intratumor blood vessel den-
sity.As a consequence, addedbevacizumab is able to further inhibit
tumor growth (Mongiat et al., 2010).
MMRN1 AND PLATELET FUNCTION
MMRN1 is a soluble S–S linked homopolymer stored in platelets,
megakaryocytes, and ECs and deposited in ECM (Hayward, 1997;
Adam et al., 2005). It supports the adhesion of platelets, neu-
trophils, and ECs via integrin αvβ3 and αIIbβ3 (Adam et al., 2005).
It binds to collagen and it is able to enhance von Willebrand
factor-dependent platelet adhesion to collagen thus supporting
thrombus formation. MMRN1 has a high afﬁnity for factor V
(Jeimi et al., 2008) and this facilitates the co-storage in platelet α-
granules. When MMRN1 is released from platelets during platelet
activation it regulates thrombin formation limiting thrombus for-
mation. This protein is playing an important homeostatic control
in platelets aggregation and its consequences. Unfortunately, all
these multiple functions have not been assigned to any of the
domains of MMRN1 apart from cell adhesion that depends on an
RGD peptide at the N-terminus (Adam et al., 2005).
gC1q-DEPENDENT FUNCTIONS
HOMOTRIMER ASSOCIATION
Several members of the C1q/TNF superfamily associate into
trimers. The chain composition of these different superfamily
members varies fromheterotrimers formedof three distinct chains
as inC1q,or of homotrimers as in collagen typesVIII (Rosenblum,
1996; Illidge et al., 1998; Greenhill et al., 2000), and X (Thomas
et al., 1991;Reichenberger et al., 1992;Chan et al., 1996; Frischholtz
et al., 1998), ACRP30 (Hu et al., 1996; Shapiro and Scherer, 1998),
MMRN1 (Hayward et al., 1995). The potential self-interaction of
the EMILIN1 gC1q domain was formally demonstrated with the
use of two-hybrid system approaches, yeast mating and cotrans-
formation that both conﬁrm the self-association of the single
protomers (Mongiat et al., 2000).
SUPRAMOLECULAR ASSEMBLY
The smallest EMILIN1 protomer under reducing conditions is a
trimer held together by strong non-covalent bonds. Likely the for-
mation of the gC1q homotrimer acts as a nucleation in a C- to
N-terminal direction, facilitating the formation of the triple helix.
Several of the gC1q domain-containing molecules assemble to
high order S–S bonded structures composed of 9–12 polypeptides
multimers, as in ACRP (Scherer et al., 1995), 18 polypeptides as in
C1q (Reid, 1983; Kishore and Reid, 2000), collagens type X (Kwan
et al., 1991), and probably also typeVIII (Sawada et al., 1990). The
sizes of MMRN1 multimers are well above 24 polypeptides (Hay-
ward et al., 1991). EMILIN1 multimers can reach sizes of several
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million daltons, corresponding to S–S bonded complexes com-
posed of several dozens of polypeptides (Mongiat et al., 2000). We
have preliminary evidence that secreted recombinant EMILIN2 is
assembled in smaller multimers compared to EMILIN1.
At present, the mechanistic basis for the formation of EMILINs
supramolecular aggregates is unknown. While covalent S–S bonds
are involved in the association it is possible that also non-covalent
interactions participate to allow supramolecular assembly. In addi-
tion, it is not clear whether each EMILIN exclusively forms homo-
typic macro-aggregates consisting of only one member or also
heterotypic macro-aggregates consisting of more members. This
latter possibility is supported, at least for EMILIN1 and EMILIN2,
by the partial overlapping gene expression pattern in vivo in many
tissues (Braghetta et al., 2002), and by the codistribution of the
secreted deposited proteins in in vitro cell cultures (Doliana et al.,
2001). In situations where both EMILINs are expressed simulta-
neously, it is theoretically possible that each EMILIN forms either
separate homotypic or that they may form heterotypic assem-
blies. The isolation of EMILIN2 from expression libraries using
the gC1q domain of EMILIN1 as a bite proved that gC1q domains
from distinct but similar molecules could interact at least in the
two-hybrid system (Doliana et al., 2001). Then, also homo- and
hetero-interactions between gC1q and EMI domains were deter-
mined by qualitative and quantitative two-hybrid assays and by
immunochemical evidence of co-expression in yeast human cell
extracts (Bot et al., in preparation). It is possible, at least in vitro,
that gC1q and EMI domains from the same or different EMILINs
interact in a head-to-tail fashion. The question remains whether
there is the need for adapter molecules that favor this interaction
or whether this interaction is direct and EMILIN1 and EMILIN2
can co-polymerize head-to-tail to form heterotypic non-covalent
multimers in vivo.
INTERACTION OF gC1q WITH α4β1 INTEGRIN
α4β1 integrin binds to the cell surface vascular cell adhesion
molecule-1 (VCAM-1) on activated endothelium (Hamann et al.,
1994) and to the ECMmolecule ﬁbronectin (FN;Humphries et al.,
1986; Komoriya et al., 1991). The key VCAM-1 binding site is the
tripeptide motif sequence IDS. This sequence is homologous to
the LDV active motif on the CS-1 peptide of FN, suggesting that
α4β1 may interact with FN and VCAM-1 through a similar mech-
anism. EMILIN1 is an adhesive ligand for α4β1 (Spessotto et al.,
2003, 2006;Verdone et al., 2008;Danussi et al., 2011) and this func-
tion is fully accounted for by the gC1q domain (Spessotto et al.,
2003). All polypeptides with integrin binding capability display
exposed aspartic or glutamic acid residues located in mobile loops
protruding from the main core of the ligand (Leahy et al., 1996;
Casasnovas et al., 1998). These residues are critical for integrin
recognition. The three dimensional conformation of the active
site on ligand–receptor binding is extensively demonstrated (in
particular for RGD containing ligands; Humphries, 1990; Leahy
et al., 1996;Arnaout et al., 2007; Barczyk et al., 2010). The aspartic-
acid-based sequences (e.g., RGD, LDV, KGD, RTD, and KQAGD)
bind to the majority of integrins (Yamada, 1991) and mutations
around the aspartic acid residue, i.e., G in RGD or L in LDV,
greatly affect integrin recognition (Pierschbacher and Ruoslahti,
1984; Komoriya et al., 1991; Cherny et al., 1993). Other integrins
interact with ligands that contain glutamic-acid-based sequences
(Michishita et al., 1993).However, it is likely that the scenario in the
EMILIN1–α4β1 interaction is more complex than in conventional
α4β1 binding to short linear peptide consensus sequences, repre-
senting the common feature of ECM integrin ligands (Humphries,
1990; Humphries et al., 2006). A gC1q domain in which the glu-
tamic acid at position 933 (E933) was substituted with an alanine
residue is no longer functional in cell adhesion assays and it is not
recognized by α4β1 integrin suggesting that this residue plays a
major role in this interaction. We exclude that the loss of activ-
ity of the E933A mutant or of deletion mutants encompassing
this residue is due to a global folding change of the protein (Ver-
done et al., 2008). Thus, the gC1q–α4β1 interaction provides a
further example of the functional relevance of disordered regions
in proteins (Radivojac et al., 2007).
How would an homotrimeric molecule such as gC1q mecha-
nistically interact with the α4β1 integrin? The explanation that a
linear tripeptide from one single monomer as in CS-1 peptide of
FN could represent the α4β1 ligand binding site on gC1q is appar-
ently excluded by the ﬁnding that the L932A mutant does not
loose its cell adhesion binding property. Several mutant residues
around E933 are still functional and this indicates that the α4β1
integrin binding site involves only E933. Thus, this residue plays
an absolutely central role in α4 integrin mediated interaction,
whereas several residues close to E933 do not seem to participate in
this interaction (Verdone et al., 2008). The NMR solved structure
locates residue E933 in the ﬂexible loop at the apex of the EMILIN1
gC1q domain assembled into a symmetric trimer. The stoichiom-
etry of three integrin molecules each recognizing one E933 residue
on the unstructured loops of the gC1q trimer is ruled out for steric
reasons. Thus, the interaction pattern with α4β1 might well entail
the binding of the three E933 carboxylate groups to a single inte-
grin molecule. An example of an integrin–ligand interaction that
requires two structural elements residing on different polypep-
tide chains has been already reported: to be recognized by αvβ3
integrin the LG1–3 globular domain of laminin α chain requires
the intact heterotrimeric C-terminal portion of the coiled-coil
domain, including the most distant C-terminal region of the β
and γ chains of laminin (Künneken et al., 2004). In that case it has
been hypothesized that the C-terminus of the γ chain is assembled
together with a speciﬁc region of LG1–3, leading to the formation
of an interchain functional ligand tripeptide. The gC1q–α4 inter-
action could represent the ﬁrst example of an integrin binding
site located on a homotrimeric assembly that employs a different
mode of integrin engagement and prospects a new model for the
interaction geometry recognition between an integrin binding site
and a functional ligand located on a homotrimeric assembly. In
this scenario we hypothesize the involvement of two/three E933
residues for a single integrin molecule engagement for a proper
interaction able to ﬁt the α4 pocket in the βMIDAS region. One
possibility to tackle this question is the use of bicistronic vectors
coding for wild type and non-functional mutant E933A gC1q in
order to obtain trimers with a single copy or two copies of the
wild type sequence on average in the homotrimer. In this systems
the mutant and wild type monomers are randomly assembled
into trimers to form a heterogeneous population and can be iso-
lated by afﬁnity chromatography. Preliminary data suggests that
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cell adhesion to heterogeneous gC1q trimers composed by both
wild type and E933A mutants, is negatively affected implying the
need of all three wild type monomers to achieve a proper integrin
ligation with the homotrimer (Capuano et al., in preparation).
FUNCTIONAL CONSEQUENCES OF THE gC1q/INTEGRIN
LIGATION
CELL ADHESION
It is known that the adhesion of α5β1 or αvβ3 integrins to FN
and vitronectin (VN) promotes a profound cytoskeletal reorgani-
zation (Ruoslahti and Pierschbacher, 1987; Deﬁlippi et al., 1999;
Ruoslahti, 1999; Zamir and Geiger, 2001; Campbell, 2008). On the
contrary, the α4β1-dependent interactions extensively studied in
hematopoietic cells (Morimoto et al., 1998; Steeber et al., 2005;
Rose et al., 2007) as well as in transfected adherent cells (Pinco
et al., 2002) prompt only the initial and intermediate stages of cell
adhesion, i.e., attachment and spreading, whereas focal adhesion
and stress ﬁber formation, characterizing strong cell adhesion, are
rarely if ever observed (Iida et al., 1995).
Contrary to common beliefs that consider α4β1 an exclu-
sive leukocyte integrin, there is a wealth of data available that
demonstrates that this integrin is widely expressed, although at
lower levels, in normal tissues including brain, heart, kidney, lung,
muscle, liver prostate, skin,andovary aswell as their tumoral coun-
terparts; α4β1 is also expressed in colon, bladder, breast, cervix,
and melanoma tumor cells (Holzmann et al., 1998). In addition,
its expression is upregulated by inﬂammatory cytokines (Weber
et al., 1996; Milner and Campbell, 2003). This data makes α4β1
an integrin which is potentially involved in multiple and extensive
interactions under several biological conditions including tumor
spread.
Cells attached to EMILIN1 display a pattern of actin and pax-
illin distribution with accumulation of rufﬂes-inducing signals
and lack of polarization and of stress ﬁber formation (Spessotto
et al., 2003). Recognition of the gC1q domain does not require
exogenous activation of α4β1 nor the addition of Mn2+ nor
anti-β1-activating mAbs; instead the presence of Ca2+ or Mg2+
is necessary since EDTA treatment fully abolishes cell adhesion
(Spessotto et al., 2003). Similar results are observed upon binding
to EMILIN2 (Spessotto et al., unpublished observations). On the
contrary, MMRN1 that possesses a RGD site binds to αvβ3 and
αIIbβ3 integrins on platelets (Adam et al., 2005).
CELL MIGRATION
Among the numerous cell types that migrate on EMILIN1 tro-
phoblasts are particularly interesting. The ﬁnding that trophoblast
cells could attach to and very efﬁciently migrate and haptorac-
tically move toward EMILIN1 using the α4β1 integrin with-
out any prior artiﬁcial cellular activation was rather unexpected
(Spessotto et al., 2006) because directional haptotaxis was much
more efﬁcient toward EMILIN1 compared with FN. In addition,
under several conditions the cooperation of MMPs with inte-
grins plays a contributing role in order to better direct cellular
migration (Deryugina et al., 2001). Accordingly, MT1-MMP is
strongly upregulated when trophoblasts cells are co-cultured with
EMILIN1-producing decidual stromal cells. The ﬁnding that the
general MMP inhibitor GM6001 is more effective and affects cell
migration toward EMILIN1 at 1-h migration, whereas at 4 h the
inhibitory effect is stronger when cells move in an α5β1 inte-
grin dependent mode toward FN (Spessotto et al., 2006), suggests
that both ligands might be involved in the uterine wall invasion
process but with a sequential role. Deposited EMILIN1 in the
uterine tissue could thus favor the initial α4β1 dependent inva-
sion by trophoblast cells to be assisted at later times by other ECM
constituents such as FN and different integrins.
CELL PROLIFERATION
It is generally known that integrin engagement positively regu-
lates cell growth (Clark and Brugge, 1995; Walker and Assoian,
2005; Gilcrease, 2007; Streuli, 2009). The ﬁnding that EMILIN1
by the direct engagement of the gC1q domain modulates skin
cell proliferation points out a novel function of α4β1 as well as
the structurally and functionally similar α9β1 integrin (Danussi
et al., 2011). The lack of integrin occupancy by EMILIN1, as it
occurs in Emilin1−/− mice, results in increased Ki67 positive cells
in epidermis and dermis. This is accompanied by reduction of
PTEN phosphatase and strong upregulation of pErk1/2. Accord-
ingly, when HT1080 and CaCo-2 cells expressing α4β1 or α9β1
integrins, respectively, adhere to gC1q PTEN levels increase. Even
the addition of soluble gC1q to cells attached to plastic upregulates
PTEN and the addition of TGF-β further increases PTEN levels.
This is accompaniedbydecreasedpErk1/2 levels and suggests a link
between PTEN and α4/α9 integrin engagement: when α4/α9 inte-
grins are not ligated by gC1qPTEN is down-regulated determining
the activation of proliferative pathways such as pAkt and pErk1/2.
Mechanistically, the increased pErk1/2 reduces TGF-β signaling
by the phosphorylation of Smad2 at inhibitory Ser245/250/255
residues. It seems likely that these downstream changes concur
in vivo to the decreased proliferation of basal keratinocytes and
dermal ﬁbroblasts (Figure 4).
ROLE OF EMILIN1 gC1q IN PHYSIOLOGICAL AND
PATHOLOGICAL CONDITIONS
Targeted inactivation of the Emilin1 gene in the mouse induces
multiple phenotypes characterized by: decreased diameter of arte-
rial vessels and systemic hypertension (Zacchigna et al., 2006); a
lymphatic phenotype with a signiﬁcant reduction of anchoring
ﬁlaments (AFs) and enlargement of lymphatic vessels leading to
a mild lymphatic dysfunction (Danussi et al., 2008); dermal and
epidermal hyperproliferation (Danussi et al., 2011). Only the last
phenotype is strictly dependent on the lack of gC1q.
EMILIN1 IN LYMPHATIC VESSEL FUNCTION
The connections between ECM and lymphatic endothelial cells
(LECs) that critically affect lymphatic vasculature function are
mediated by AFs (Swartz and Skobe, 2001). These ﬁbrillin rich
structures, which are part of a hierarchical ﬁbrillar elastic appa-
ratus (Gerli et al., 2000), are highly sensitive to interstitial stresses
(Swartz and Skobe, 2001) and exert a signiﬁcant tension on LECs:
their main function is to widen the capillary lumen and open
the overlapping cell junctions facilitating lymph formation (Cueni
and Detmar, 2006). Abnormalities of AFs may reduce adsorption
from interstitium and propulsion of lymph and cells and promote
pathological conditions such as lymphedema or diseases related to
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FIGURE 4 | Elastin microfibrillar interface protein 1 in skin homeostasis.
This illustration summarizes the proposed molecular mechanism underlying
the regulatory role of EMILIN1 in skin.When EMILIN1 is expressed (left)
TGF-β triggers cytostatic signals via pSmad2 (Ser465/467), down-modulates
PI3K/Akt and hence PTEN expression is increased also because EMILIN1
binds to α4/α9β1 integrins. PTEN activation then inhibits the pro-proliferative
activity of pErk1/2.When EMILIN1 is not present (right) the increased levels
of mature TGF-β and the lack of α4/α9β1 integrin speciﬁc engagement
downregulates PTEN determining the activation of the pro-proliferative pAkt
and pErk1/2 pathways. In addition, TGF-β signaling is reduced since
Erk1/2-phosphorylates the inhibitory Ser245/250/255 residues of
Smad2.
impaired immune responses (De Cock et al., 2006). Dysfunctions
may also be induced by extensive and chronic degradation of the
ECM that renders lymphatic vessels non-responsive to the changes
in the interstitium (Pelosi et al., 2007).
Consistent with the absence of a basement membrane
in vivo (Pepper and Skobe, 2003), LECs secrete very little ECM
(Farnsworth et al., 2006). EMILIN1 is produced by LECs in vitro
and is present at the abluminal side of lymphatic vessels. It forms
ﬁbers directed from LECs to the surrounding ECM. Therefore,
the detection of abundant EMILIN1 suggested the involvement
of this protein in the structure and function of lymphatic vessels
(Danussi et al., 2008). In fact, a comparative study between wild
type and Emilin1−/− mice highlighted that Emilin1−/− mice dis-
play hyperplasia and enlargement of lymphatic vessels compared
to wt mice. Morphological alterations of the lymphatic vessels of
Emilin1−/− mice also are evident at the ultrastructural level. Struc-
tural abnormalities such as the reduction in the number of AFs and
the formation of extensive multiple overlapping junctions of LECs
are among the most evident alterations. LECs in Emilin1−/− mice
frequently appear detached from the underlying ECM and from
each other and result in the formation of irregular and multi-
ple intraluminal ﬂaps suggesting that EMILIN1 is involved in the
process of lymphatic remodeling observed in these mice (Danussi
et al., 2008). These alterations are associatedwith inefﬁcient lymph
drainage, enhanced lymph leakage, and lymphedema. However, in
contrast to other recently described lymphatic-lineage gene tar-
geting in mouse models, that in most cases result embryonic or
perinatal lethal (Tammela et al., 2005), homozygous disruption
of Emilin1 gene induces only a mild phenotype. Notably, this
is the ﬁrst abnormal lymphatic phenotype associated with the
deﬁciency of an ECM protein. Finally, the valve defects observed
in collecting vessels are grossly similar to those of α9 integrin
null mice (Bazigou et al., 2009), suggesting that the interaction
of EMILIN1 and α9 integrin demonstrated with basal skin ker-
atinocytes (Danussi et al., 2011) may also be important in valve
morphogenesis in LECs.
EMILIN1 IN SKIN HOMEOSTASIS
The phenotype of the Emilin1−/− mouse skin revealed increased
thickness of epidermis and dermis.
Elastin microﬁbrillar interface protein 1 interacts with α4β1
(expressed on ﬁbroblasts) and the closely related α9β1 (expressed
on keratinocytes) to provide an important external cue for
the maintenance of a correct homeostasis between proliferation
and differentiation (Danussi et al., 2011). In this context, sig-
nals emanating from EMILIN1-ligated α4/α9 integrins are anti-
proliferative (Danussi et al., 2008, 2011). But how does EMILIN1
brings about the control of cell proliferation? EMILIN1 is pro-
duced only by skin ﬁbroblasts and it is deposited in the dermis
where it is abundantly expressed. However, EMILIN1-positive ﬁb-
rils depart from near the BM and reach the basal keratinocyte
layer, thus connecting the epidermis to the underlying dermal
layer. In vitro co-cultures of EMILIN1-producing ﬁbroblasts and
keratinocytes provided the formal demonstration that the con-
tact between deposited EMILIN1 and α4/α9 integrins directly
regulates cell proliferation: only “contact” and not “transwell”
(so that the two cell types are physically separated) co-cultures
of keratinocytes with wild type EMILIN1-producing ﬁbroblasts
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inhibits proliferation. Consequently, silencing of EMILIN1 stim-
ulates the proliferation of co-cultured keratinocytes. Proliferative
and anti-proliferative signals occur simultaneously and the lat-
ter, EMILIN1/gC1q ligation in this case, can override the pro-
proliferative signals only when they reach a certain threshold
(Müller et al., 2008). It is likely that under certain circumstances
the pericellular concentration of EMILIN1 in basal keratinocytes
(andﬁbroblasts) exceeds this threshold and stops cell proliferation.
Our ﬁndings open new perspectives in the molecular mechanisms
of quiescence versus proliferation in basal keratinocytes. In addi-
tion, given the high expression of α9β1 integrin on these cells, the
demonstration that EMILIN1 is a novel ligand for this integrin
(Danussi et al., 2011) supports a scenario in which one of the
functional consequences is the integration of EMILIN1 into the
complex connections of basal keratinocyte turn over and the cross
talks between basal keratinocytes, underlying ECM and stromal
cells.
EMILIN1 IN CANCER DEVELOPMENT
In Emilin1−/− mice subjected to a skin carcinogenesis protocol
tumor appearance was signiﬁcantly accelerated and the number
and size of tumors compared to wild type mice increased (Danussi
et al., submitted). It seems likely that the aberrant skin homeosta-
sis generated by EMILIN1 deﬁciency in these mice (Danussi et al.,
2011) induced apro-tumorigenic environment. Functional studies
support the hypothesis that PTEN is a critical tumor suppressor for
skin cancer in humans and in mice (Di et al., 1998; Segrelles et al.,
2002; Suzuki et al., 2003; Komazawa et al., 2004) by negatively reg-
ulating signal pathways involved in cell proliferation (Schindler
et al., 2009). In Emilin1−/− mice the lack of EMILIN1 ligation
of α4β1/α9β1 integrins reduces the expression of PTEN also in
the skin tumor environment. One attractive hypothesis assumes
that the mechanisms controlling the homeostasis of cell prolifera-
tion and hence the enhanced tumor development when EMILIN1
expression is genetically or functionally knocked down depends
on the unique mode of gC1q–α4β1/α9β1 integrin interaction.
We are conﬁdent that the elucidation of the ﬁne molecular
interactions between α4β1/α9β1 integrins and the E933 residue(s)
on the unstructured loops of the gC1q trimer and the downstream
signaling events will help clarify the numerous gC1q-dependent
cellular responses.
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